Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Kenvue Inc.

Talc Litigation Attorneys Allege ‘Bad Faith Filings,’ ‘Fraudulent Activities’ By J&J In Bankruptcy

Attorneys for some plaintiffs alleging harm from talc products J&J marketed ask a court to order the firm, along with a subsidiary holding company it created in 2021 to manage its talc liabilities and immediately placed in bankruptcy, to provide emails and other communications among in-house counsel and compel their testimony.

Cosmetics OTC Drugs

Supreme Court Decision Derailing Purdue Pharma Bankruptcy Could Trip J&J Talc Litigation Strategy

Supreme Court ruling on Purdue bankruptcy should “derail any attempt by J&J to return the talc litigation to the bankruptcy courts,” says class action plaintiff’s attorney. A federal court, Justice Gorsuch states, relieved Purdue owners of liability “without securing the consent of those affected or placing anything approaching their total assets on the table.”

OTC Drugs Litigation

Titans Of Pharma: J&J Back On Top For CEO Remuneration

J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.

Leadership Companies

Kenvue Makes Progress Transitioning From J&J Cash Stream To ‘Profitable Growth’ On Its Own

For Kenvue, 2023 “was really about separating from J&J” as a segment “mostly focused on profit and cash,” says CEO Thibaut Mongon. “But in 2024, you see a very different Kenvue in action.”

Consumer M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer